Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH375 monotherapy in previously treated KRAS G12D-mutant metastatic pancreatic cancer (Phase II)
CTR20252136Phase 2Terminated
- Sponsor
- GenFleet Therapeutics
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GFH375 in pancreatic cancer (PC), sponsored by GenFleet Therapeutics. Started May 2025; status: terminated.
02
Drugs
GFH375
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20252136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252136.